Matches in SemOpenAlex for { <https://semopenalex.org/work/W2101215929> ?p ?o ?g. }
- W2101215929 endingPage "985" @default.
- W2101215929 startingPage "977" @default.
- W2101215929 abstract "Background Many patients with venous leg ulcers do not heal with standard care. HP802-247 is a novel spray-applied cell therapy containing growth-arrested allogeneic neonatal keratinocytes and fibroblasts. We compared different cell concentrations and dosing frequencies of HP802-247 for benefit and harm when applied to chronic venous leg ulcers. Methods We enrolled adult outpatients from 28 centres in the USA and Canada with up to three ulcers, venous reflux confirmed by doppler ultrasonography, and adequate arterial flow in this phase 2, double-blind, randomised, placebo-controlled trial if at least one ulcer measured 2–12 cm2 in area and had persisted for 6–104 weeks. Patients were randomly assigned by computer-generated block randomisation in a 1:1:1:1:1 ratio to 5·0×106 cells per mL every 7 days or every 14 days, or 0·5×106 cells per mL every 7 days or every 14 days, or to vehicle alone every 7 days. All five groups received four-layer compression bandages. The trial sponsor, trial monitors, statisticians, investigators, centre personnel, and patients were masked to treatment allocation. The primary endpoint was mean percentage change in wound area at the end of 12 weeks. Analyses were by intention to treat, excluding one patient who died of unrelated causes before first treatment. This trial is registered with ClinicalTrials.gov NCT00852995. Findings 45 patients were assigned to 5·0×106 cells per mL every 7 days, 44 to 5·0×106 cells per mL every 14 days, 43 to 0·5 ×106 cells per mL every 7 days, 46 to 0·5 ×106 cells per mL every 14 days, and 50 to vehicle alone. All required visits were completed by 205 patients. The primary outcome analysis showed significantly greater mean reduction in wound area associated with active treatment compared with vehicle (p=0·0446), with the dose of 0·5 ×106 cells/mL every 14 days showing the largest improvement compared with vehicle (15·98%, 95% CI 5·56–26·41, p=0·0028). Adverse events were much the same across all groups, with only new skin ulcers and cellulitis occurring in more than 5% of patients. Interpretation Venous leg ulcers can be healed with a spray formulation of allogeneic neonatal keratinocytes and fibroblasts without the need for tissue engineering, at an optimum dose of 0·5×106 cells per mL every 14 days. Funding Healthpoint Biotherapeutics." @default.
- W2101215929 created "2016-06-24" @default.
- W2101215929 creator A5009815393 @default.
- W2101215929 creator A5010117182 @default.
- W2101215929 creator A5023217122 @default.
- W2101215929 creator A5029285415 @default.
- W2101215929 creator A5039762565 @default.
- W2101215929 creator A5045611437 @default.
- W2101215929 date "2012-09-01" @default.
- W2101215929 modified "2023-10-15" @default.
- W2101215929 title "Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial" @default.
- W2101215929 cites W1976417206 @default.
- W2101215929 cites W1979962141 @default.
- W2101215929 cites W1987876453 @default.
- W2101215929 cites W2000314257 @default.
- W2101215929 cites W2001770668 @default.
- W2101215929 cites W2024968570 @default.
- W2101215929 cites W2031687624 @default.
- W2101215929 cites W2033581904 @default.
- W2101215929 cites W2036484524 @default.
- W2101215929 cites W2039135573 @default.
- W2101215929 cites W2039941561 @default.
- W2101215929 cites W2040757456 @default.
- W2101215929 cites W2043155505 @default.
- W2101215929 cites W2049043712 @default.
- W2101215929 cites W2055448391 @default.
- W2101215929 cites W2060868853 @default.
- W2101215929 cites W2063715027 @default.
- W2101215929 cites W2067691626 @default.
- W2101215929 cites W2075966664 @default.
- W2101215929 cites W2078919314 @default.
- W2101215929 cites W2111065446 @default.
- W2101215929 cites W2114055467 @default.
- W2101215929 cites W2115852450 @default.
- W2101215929 cites W2122531041 @default.
- W2101215929 cites W2130322452 @default.
- W2101215929 cites W2134150152 @default.
- W2101215929 cites W2145490184 @default.
- W2101215929 cites W2161357321 @default.
- W2101215929 cites W267982658 @default.
- W2101215929 doi "https://doi.org/10.1016/s0140-6736(12)60644-8" @default.
- W2101215929 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22863328" @default.
- W2101215929 hasPublicationYear "2012" @default.
- W2101215929 type Work @default.
- W2101215929 sameAs 2101215929 @default.
- W2101215929 citedByCount "148" @default.
- W2101215929 countsByYear W21012159292012 @default.
- W2101215929 countsByYear W21012159292013 @default.
- W2101215929 countsByYear W21012159292014 @default.
- W2101215929 countsByYear W21012159292015 @default.
- W2101215929 countsByYear W21012159292016 @default.
- W2101215929 countsByYear W21012159292017 @default.
- W2101215929 countsByYear W21012159292018 @default.
- W2101215929 countsByYear W21012159292019 @default.
- W2101215929 countsByYear W21012159292020 @default.
- W2101215929 countsByYear W21012159292021 @default.
- W2101215929 countsByYear W21012159292022 @default.
- W2101215929 countsByYear W21012159292023 @default.
- W2101215929 crossrefType "journal-article" @default.
- W2101215929 hasAuthorship W2101215929A5009815393 @default.
- W2101215929 hasAuthorship W2101215929A5010117182 @default.
- W2101215929 hasAuthorship W2101215929A5023217122 @default.
- W2101215929 hasAuthorship W2101215929A5029285415 @default.
- W2101215929 hasAuthorship W2101215929A5039762565 @default.
- W2101215929 hasAuthorship W2101215929A5045611437 @default.
- W2101215929 hasConcept C126322002 @default.
- W2101215929 hasConcept C141071460 @default.
- W2101215929 hasConcept C142724271 @default.
- W2101215929 hasConcept C168563851 @default.
- W2101215929 hasConcept C203092338 @default.
- W2101215929 hasConcept C204787440 @default.
- W2101215929 hasConcept C27081682 @default.
- W2101215929 hasConcept C2780952370 @default.
- W2101215929 hasConcept C535046627 @default.
- W2101215929 hasConcept C71924100 @default.
- W2101215929 hasConceptScore W2101215929C126322002 @default.
- W2101215929 hasConceptScore W2101215929C141071460 @default.
- W2101215929 hasConceptScore W2101215929C142724271 @default.
- W2101215929 hasConceptScore W2101215929C168563851 @default.
- W2101215929 hasConceptScore W2101215929C203092338 @default.
- W2101215929 hasConceptScore W2101215929C204787440 @default.
- W2101215929 hasConceptScore W2101215929C27081682 @default.
- W2101215929 hasConceptScore W2101215929C2780952370 @default.
- W2101215929 hasConceptScore W2101215929C535046627 @default.
- W2101215929 hasConceptScore W2101215929C71924100 @default.
- W2101215929 hasIssue "9846" @default.
- W2101215929 hasLocation W21012159291 @default.
- W2101215929 hasLocation W21012159292 @default.
- W2101215929 hasOpenAccess W2101215929 @default.
- W2101215929 hasPrimaryLocation W21012159291 @default.
- W2101215929 hasRelatedWork W1859326399 @default.
- W2101215929 hasRelatedWork W1966127473 @default.
- W2101215929 hasRelatedWork W1974781192 @default.
- W2101215929 hasRelatedWork W1992458659 @default.
- W2101215929 hasRelatedWork W2074965717 @default.
- W2101215929 hasRelatedWork W2081991953 @default.
- W2101215929 hasRelatedWork W2085650940 @default.
- W2101215929 hasRelatedWork W2119160676 @default.